Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThis update changes the ClinicalTrials.gov page’s displayed revision/version from v3.5.0 to v3.5.3, indicating an internal platform release without altering the study information presented.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision label updated to v3.5.0; the previous v3.4.3 label was removed.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check91 days agoChange DetectedThe visible change is a minor revision label updated from v3.4.1 to v3.4.2; no alterations to the study content, eligibility criteria, or essential page functionality are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check98 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check99 days agoChange DetectedThe page shows a minor version update from v3.4.0 to v3.4.1. There are no observed changes to core study content, eligibility criteria, or outcomes; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.